Breast Cancer | Aditya Bardia, MD, MPH

Chemo Side Effects: What to Expect and How to ManageПодробнее

MOASC's Spotlight on Cancer ResearchПодробнее

Dr Bardia on Current Approaches to HER2+ Breast Cancer ManagementПодробнее

Exploring the Treatment Landscape for Triple-Negative Breast CancerПодробнее

Empowering Changes and Revolutionizing Treatment and Equity in Breast CancerПодробнее

State of the Art: Targeting Mutant ERПодробнее

A Look at the Therapeutic Landscape for Metastatic Breast CancerПодробнее

Part 2 - Molecular and Precision Medicine (MAP) SeriesПодробнее

Ask the Expert: Understanding the Latest Advances in Breast CancerПодробнее

SABCS Snippets: DESTINY-Breast06 Phase III TrialПодробнее

Community Context: Integrating TROP2-Targeting ADCs Into Patient-Centric Breast Cancer CareПодробнее

EMERALD: elacestrant vs. SOC for patients with ER+ HER2- metastatic breast cancerПодробнее

Navigating the Expanding Treatment Arsenal for ER+/HER2- Breast CancerПодробнее

ASCO 2021 Highlights in Breast Cancer Aditya Bardia, MDПодробнее

Dr. Aditya Bardia | San Antonio Breast Cancer Symposium 2022 | General SessionПодробнее

Science Impacting Cancer Care: Translational Medicine and Supportive Care ResearchПодробнее

Expanding Treatment Options in ER+/HER2- Breast Cancer: SERDs, SERMs, SERCAs, and MoreПодробнее

SERDs at the Inflection Point in Pretreated ER+/HER2- Breast Cancer: Novel ER-Targeting TherapiesПодробнее

AMEERA-5: amcenestrant + palbociclib for previously untreated ER+/HER2- advanced breast cancerПодробнее

TROPION-PanTumor01: datopotamab deruxtecan in advanced HER2+ breast cancerПодробнее